Due to the involvement of vascular endothelial growth factor (VEGF) in the development of new blood vessels, anti-angiogenicsor anti-VEGF agents can cause regression of the abnormal blood vessels and improve vision when injected directly into the vitreous humour of the eye. The injections must be repeated monthly or bimonthly.
Several anti-angiogenic drugs have been approved for use in the eye by the FDA and regulatory agencies around the world. Ranibizumab is a smaller fragment, Fab fragment, of the parent bevacizumab molecule specifically designed for eye injections. Other approved anti-angiogenicdrugs for the treatment of neo-vascular AMD include pegaptaniband aflibercept. One of the key issue facing the therapeutic area is patient compliance to painful and frequent intra-vitreal injections.
Eyevensys aims at improving treatment efficacy as well as compliance by developing EYS609 a device-plasmid combination method to express a well-established anti-VEGF compound in-situ in the eye over extended periods of time.
Animal proofs of concept show very promising results in terms of expression of the anti-VEGF compounds which have been tested and the potential to inhibit choroidal neovascularization in the CNV model in rats.